Xoma turns its attention to Repare

Repare Therapeutics is the latest biotech to be scooped up by the royalty specialist Xoma Royalty, which will once again use its XenoTherapeutics subsidiary, a vehicle it deployed for the Essa Pharma acquisition over the summer. For Repare, the end has been a long time coming. The company’s fortunes began to unravel early last year when Roche exited an ATR inhibitor collaboration, triggering a drawn-out struggle to stay afloat. Two restructurings later, the last cutting 75% of staff, and with development of its most advanced programme, camonsertib, put on hold pending a partner, Repare has ultimately accepted a sale. Xoma will acquire the company, which had $112.6m in cash as of September 2025, for $78.2m. The deal additionally includes a contingent value right that could bring an additional 75-90% of the net proceeds from Repare's existing collaborations with Bristol Myers Squibb, Debiopharm and DCX Therapeutics; 100% of the proceeds from future licensing deals for the Polθ inhibitor RP-3467, the PLK4 inhibitor RP-1664, and camonsertib; and half the net proceeds for any deals covering Repare’s remaining projects. However, these remain long shots.

Xoma’s recent oncology transactions

Source: OncologyPipeline.